ArticleiScience2026
USP18 promotes clear cell renal cell carcinoma progression by regulating the ubiquitination and stability of YBX3.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Clinicopathological significance and exploratory prognostic modeling of USP18 and YBX3 expression in clear cell renal cell carcinoma: a retrospective Chinese cohort study.Frontiers in oncology · 2026Article
- YBX1 as an adaptive RNA hub in cancer: linking state-dependent RNA regulation to tumor immunity, metabolic reprogramming, and therapy resistance.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Y box binding protein 3 (YBX3) is an oncogene in clear cell renal cell carcinoma (ccRCC). This study aimed to investigate ubiquitin-specific proteases (USPs) that regulate YBX3 stability in ccRCC. USP18 was identified as a potent stabilizer of YBX3, and USP18 was depleted to assess its impact on the malignant behavior of ccRCC cells and on YBX3 ubiquitination. Subsequently, YBX3 was overexpressed in USP18-deficient cells to determine whether it could rescue the attenuated malignant phenotypes. A xenograft model and ccRCC organoids were also used to examine the effect of USP18 on ccRCC. USP18 knockdown caused reduced viability, arrested cell cycle, increased apoptosis, attenuated migration and invasion of ccRCC cells. Mechanistically, USP18 reduces ubiquitination and stabilizes YBX3 in ccRCC cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.